期刊文献+

21例血栓性血小板减少性紫癜临床研究 被引量:13

Twenty-one patients with thrombotic thrombocytopenic purpura:a clinical study
原文传递
导出
摘要 目的:探讨血栓性血小板减少性紫癜(thrombotic thrombocytopenic purpura,TTP)的临床特征、治疗及预后。方法将南京医科大学第一附属医院2006年4月至2013年1月诊断的TTP患者21例,分成有效组和死亡组,进行回顾性分析。其中男性6例,女性15例,年龄(46.81±12.17)岁。纳入标准:(1)无明显原因的血小板减少(<100×10^9 L^-1);(2)溶血性贫血,Coombs’试验阴性,外周血涂片出现碎裂红细胞;(3)符合上述标准的TTP患者,其临床表现及病程均被纳入本研究。排除标准:(1)<24 h出院或死亡;(2)在外院已接受血浆置换治疗;(3)病历资料不完整;(4)无法随访;(5)排除其他血栓性微血管病。应用统计分析软件SPSS 20.0对患者一般情况、病因、临床特征、治疗和预后进行分析。符合正态分布的计量资料用(x ± s)表示,组间比较使用t检验;分类资料以频数表示,使用Fisher确切概率法进行比较。P<0.05为差异具有统计学意义。结果21例患者均有血小板减少及微血管病性溶血性贫血表现,12例(57.2%)出现典型TTP五联征(发热、血小板减少、微血管病性溶血性贫血、神经系统症状和肾脏损害),2例(9.5%)仅表现为三联征(血小板减少、微血管病性溶血性贫血、神经系统症状),7例(33.3%)出现四种临床表现(三联征加上发热或肾脏损害);本组接受血浆置换治疗者7例,有效率71.4%。结论 TTP病情进展迅速,血浆置换是治疗TTP的首选方法,病因治疗有助于控制病情。 Objective To investigate clinical features, outcomes and laboratory findings of thrombotic thrombocytopenic purpura (TTP).Methods Patients with TTP admitted between April 2006 and January 2013 were identified by a retrospective review of records.Totally 21 patients were available,15 females and 6 males,with a median age of 46 years (ranged 18-66).The diagnostic criteria were defined by:(1)thrombocytopenia (〈100 ×^9 L^-1)without other identifiable causes;(2)a negative Coombs'test and hemolytic anemia with schistocytes on the peripheral blood smear;and only those patients meeting the criteria for TTP,both on clinical presentation and their clinical course,were included in this study. Exclusion criteria were:(1)patients discharged or dead within 24 hours after admission;(2)patients treated with plasma exchange therapy in other hospitals;(3)medical data were incomplete;(4)cannot be followed up;and (5 )other causes of thrombotic microangiopathies.General condition of patients,etiology, clinical features,treatment and prognosis were analyzed by using the SPSS 20.0 software.P value of 〈0.05 was considered as significant.Results Hemolytic anemia and thrombocytopenia appeared in all of the patients. Twelve patients (57.2%) had the classical pentad manifestations of TTP (fever, thrombocytopenia,microangiopathic hemolytic anemia,symptoms of nervous system,renal injury),seven patients (33.3%)had tetrad of TTP clinical manifestations (thrombocytopenia,microangiopathic hemolytic anemia,symptoms of nervous system,fever or renal injury),and only two patients showed the triad manifestations of TTP (thrombocytopenia, microangiopathic hemolytic anemia, symptoms of nervous system).In our studies,seven patients accepted plasmapheresis,and five of them (71.4%)achieved remission.Conclusions TTP progresses quickly.Plasmapheresis is still the treatment of choice for TTP patients.Etiological treatment can help to control the conditions of patients with TTP.
出处 《中华急诊医学杂志》 CAS CSCD 北大核心 2014年第6期673-677,共5页 Chinese Journal of Emergency Medicine
关键词 血栓性血小板减少性紫癜 血浆置换 病因治疗 ADAMTS13 预后 Thrombotic thrombocytopenic purpura (TTP) Plasmapheresis (PE) Etiological treatment ADAMTS13 Clinical study Prognosis
  • 相关文献

参考文献28

  • 1Zhou Z. Von Willebrand factor, ADAMTS 13, and thrombotic Thrombocytopenic purpura [J]. Semin Thromb Hemost, 2010, 36 (1): 71-81.
  • 2Moake J. Thrombotic microangiopatbies: multimers, metalloprotease, and beyond [J]. Clin & Trans Sci, 2009, 2 (5): 366-373.
  • 3Gurkan E, Baslamisli F, Guvenc B, et al. Thrombotic tlrrombocytopenic purpura in southern Turkey: a single-center experience of 29 cases [J]. Clin lab Haemato, zos, Tl (2): 121-125.
  • 4George IN, Terrell DR, Swisher KK, et al. Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry [J]. J Clin Apheresis , 2008, 23 (4): 129-137.
  • 5Furlan M. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura [J]. Exp Rev Card Ther, 2003,1 (2): 243-255.
  • 6Sadler JE. von Willebrand factor in its native environment [J]. Blood, 2013, 121 (14): 2583-2584.
  • 7Shah N, Rutherford C, Matevosyan K, et al. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TIP) [J]. Brit J Haem, 2013, 163: 514-519.
  • 8Shelat SG, Smith AG, AI J, et al. Inhibitory autoantibodies against ADAMTS13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS13 protease and may accelerate its clearance in vivo [J]. Thromb Haemost, 2006, 4 (8): 1707-1717.
  • 9Reese J, Darrshini A, Muthurajah S, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired adamts13 deficiency: comparison of incidence, demographic and clinical features [J]. Pediatr Blood Cancer, 2013,60 (10): 1676-1682.
  • 10汤屹,周剑锋,孟力,刘文励,孙汉英,张义成,张东华.血小板减少相关性多器官功能障碍综合症患者ADAMTS13的研究进展[J].中华急诊医学杂志,2009,18(5):556-558. 被引量:3

二级参考文献26

  • 1Nguyen TC, Careillo JA. Bench-to-bedside review: thrombocytopeniaassociated multiple organ failure-a newly appreciated syndrome in the critically ill[J]. Crit Care,2006,10(6) :235-242.
  • 2Lattuada A, Rossi E, Calzarossa C, et al. Mild to moderate reduction of a yon Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome [ J ]. Haematologica, 2003,88(9) : 1029-1034.
  • 3Amoura Z, Costedoat-Chalumeau N, Veyradier A, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome [ J ]. Arthritis Rheum. 2004,50(10) : 3260-3264.
  • 4Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure[J]. Blood, 2006,107(2) :528-534.
  • 5Bernhard Lammle, Johanna A. Kremer Hovinga, et al. Acquired thrombotic thrombocytopenic pucpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease[J]. haematologica, 2008, 93(2) : 172-177.
  • 6Antonella L, Edoardo R, Cinzia C, et al. Mild to moderate reduction of a yon willebrand factor cleaving protease(ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome[J]. J of hematology, 2003, 88(9) : 1029-1034.
  • 7Shibagaki Y, Fujita T. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/thrombotic thrombocy- topenic purpura (TIP): can we differentiate one from the other? [J]. Hypertens Res, 2005,28( 1 ) : 89-95.
  • 8Amoura Z, Costedoat-Chalumeau N, Veyradier A, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome [J]. Arthritis Rheum, 2004,50(10) : 3260-3264.
  • 9Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of yon willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure[J]. Blood, 2006,107(2) :528-534.
  • 10Nguyenl TC, Liu A, Liu L, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis[ J]. Haematologica, 2007,92( 1 ): 121-124.

共引文献7

同被引文献89

  • 1黄汉美.妊娠合并特发性血小板减少性紫癜110例临床分析[J].中国药物经济学,2013,8(S2):342-343. 被引量:2
  • 2何礼贤.肺孢子菌肺炎的诊断与治疗[J].中华结核和呼吸杂志,2007,30(11):802-805. 被引量:24
  • 3Pels SG,Paidas MJ. Microangiopathic disorders in pregnan- cy[J]. Hematol Oncol Clin North Am,2011,25(2) :311-322.
  • 4Yun Yan, Zhang Dongxia, Han Xuanmao, et al. Diagnosis and treatment of thrombotic thrombocytopenic purpura clinical experience[J]. Thrombosis and Hemostasis Sci- ence ,2011,17(6) :262-265.
  • 5秦红,孙惠,文艳敏.妊娠期高血压综合征产妇妊娠结局的临床分析[J].医药前沿,2014,(28):167-168.
  • 6Zhon Z. VonWillebrand factor, ADAMTS B, and thrombotic Thrombocytopenic purpura[J]. Semin Thromb Hemost, 2010,36 ( 1 ) : 71- 81.
  • 7Furlan M, Robles R, Lamie B,et al. Partia 1 purification and charac- terization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis[J]. Blood, 1996, 87(10) :4223 -4234.
  • 8Sadler JE. Biochemistry and genetics of yon Willebrand factor [J]. Annu Rev Biochem,1998,67(4) :395 -424.
  • 9Banno F, Kokame K, Okuda T, et al. Complete deficiency in AD- AMTS13 is prothrombotic, but it alone is not suffident to cause thrombotic thrombocytopenic purpura [J ]. Blood, 2006, 107 ( 8 ) 3161-3166.
  • 10Shelat SG,Smith AG, Ai J, et al. Inhibitory autoantibodies against ADAMTSB in patients with thrombotic thrombocytopenic purpura bind ADAMTS13 protease and may accelerate its clearance in vivo [J]. J Thromb Haemost,2006,4(8) :1707-1717.

引证文献13

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部